Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Treatment With Oseltamivir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* exposure to influenza during hospitalization~* risk factors for influenza complications~* consent for participation obtained~Exclusion Criteria:~* younger than 18 years~* hematological malignancy~* hospitalized in intensive care unit~* refusal to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 days (Type: ACTIVE_COMPARATOR): oral oseltamivir 75 mg once daily for 5 days post-exposure
- 10 days (Type: ACTIVE_COMPARATOR): oral oseltamivir 75 mg once daily for 10 days post-exposure

Based on this trial design, predict the completion outcome and termination type (if applicable).